Webinar: **Optimizing Ovarian Cancer Treatment: Expert Perspectives on Evolving Standards**

**Date:** 24 September 2025  
**Time:** 18:00 – 20:00   
**Format:** Virtual, interactive (Zoom Meeting)

**Scientific Content Objectives**

* First-Line Treatment (1L)
  + Overview of current options and key distinctions for low-risk vs. high-risk patients.
  + Importance of biomarker-driven decisions, combination strategies (IO, PARP, Bev).
  + Discussion around Paola-1 and future impact of ASCO data on clinical practice.
* Second-Line / Recurrent Treatment (2L)
  + Treatment decisions post-1L maintenance.
  + Focus on platinum-resistant disease, new agents like HER2 ADC, FRα ADC (but not too deeply).
  + Biomarker-driven approaches (HER2, BRCA, HRD, FRα), with consideration of Swiss vs. French prescribing practices.

|  |  |  |
| --- | --- | --- |
| **Time** | **Agenda Item** | Dr. Apostolos Sarivalasis |
| 18:00–18:05 | Welcome & Opening Remarks | All |
| 18:05–18:25 | **Presentation 1:** First-Line Ovarian Cancer – Treatment Evolution & Future Options (incl. IO combinations, stratification) | Prof. Isabelle Ray-Coquard |
| 19:15–19:30 | **Case Study:** BRCA+ Patient in Recurrent Setting | Dre Anna Durigova |
| 19:30–19:50 | **Discussion & Q&A** (Roundtable, interactive) | All |
| 19:50–20:00 | Closing Remarks & Next Steps | Dr. Apostolos Sarivalasis |

**Notes:**

* Presentations are short and focused (15–20 mins) to maintain engagement.
* Case studies are used to stimulate discussion and practical peer exchange.
* Attendees will be able to ask live questions or submit in advance.